Stock TELO TELOMIR PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Telomir Pharmaceuticals, Inc.

Equities

TELO

US87975F1049

Real-time Estimate Cboe BZX
Other stock markets
 12:17:42 2024-07-05 pm EDT 		5-day change 1st Jan Change
3.835 USD +2.27% Intraday chart for Telomir Pharmaceuticals, Inc. -20.37% 0.00%
Jul. 02 Telomir Pharmaceuticals Joins Russell 3000, Microcap Indexes MT
Jul. 01 Telomir Pharmaceuticals, Inc.(NasdaqCM:TELO) added to Russell Small Cap Comp Value Index CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes
AQ
Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel
AQ
Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1
AQ
Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support
AQ
Telomir Pharmaceuticals sees breakthrough potential in Anti-Aging Treatment with Telomir 1
AQ
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.
AQ
Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024
AQ
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
AQ
Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th
AQ
Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate’s Potential in DNA Age Reversal Science
AQ
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference
AQ
Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal
AQ
Telomir Pharmaceuticals Announces Closing of Initial Public Offering
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TELO Stock
  4. News Telomir Pharmaceuticals, Inc.
  5. Press Releases